{"id":25618,"date":"2026-02-24T08:05:35","date_gmt":"2026-02-24T13:05:35","guid":{"rendered":"https:\/\/medicarereport.org\/?p=25618"},"modified":"2026-02-24T08:05:37","modified_gmt":"2026-02-24T13:05:37","slug":"the-fda-creates-a-quicker-path-for-gene-therapies","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=25618","title":{"rendered":"The FDA creates a quicker path for gene therapies"},"content":{"rendered":"\n<p>(By Rob Stein for NPR)<\/p>\n\n\n\n<p>The Food and Drug Administration Monday unveiled the details of a new policy designed to make it easier and quicker for patients with very rare diseases to get cutting-edge treatments.  Continue reading<a href=\"https:\/\/www.npr.org\/2026\/02\/23\/nx-s1-5720948\/fda-rare-disease-gene-therapy\" data-type=\"link\" data-id=\"https:\/\/www.npr.org\/2026\/02\/23\/nx-s1-5720948\/fda-rare-disease-gene-therapy\"> here&#8230;<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"54\" class=\"wp-image-3902\" style=\"width: 150px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo.png 152w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/08\/NPR-logo-150x55.png 150w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:<\/strong>\u00a0The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Rob Stein for NPR) The Food and Drug Administration Monday unveiled the details of a new policy designed to<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31,15],"tags":[76,2027],"class_list":["post-25618","post","type-post","status-publish","format-standard","hentry","category-fda","category-part-dprescription-drugs","tag-fda","tag-gene-therapies"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/25618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25618"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/25618\/revisions"}],"predecessor-version":[{"id":25619,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/25618\/revisions\/25619"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}